Clinical Trials on Myositis in South Africa

Total 48 results

Abcuro, Inc.

Active, not recruiting

A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)

Inclusion Body Myositis

Australia
University of Kansas Medical Center
The Perron Institute

Recruiting

Phase III Trial of Sirolimus in IBM

Inclusion Body Myositis

United States, Australia
Regeneron Pharmaceuticals

Recruiting

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA)

Fibrodysplasia Ossificans Progressiva

Japan, United States, Korea, Republic of, Spain, France, Australia, United Kingdom, China, Poland, Malaysia, Italy, Finland, Hong Kong, South Africa, Chile, Brazil, Netherlands, Colombia
Sanofi

Completed

Immunogenicity and Safety of Pentaxim in South African Infants

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Infections

South Africa
Sanofi

Completed

Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis

South Africa
Incyte Corporation

Recruiting

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (Progress)

Fibrodysplasia Ossificans Progressiva (FOP)

United States, France, Korea, Republic of, Spain, Italy, United Kingdom, Russian Federation, China, Australia, Brazil, Mexico, New Zealand, Argentina, Canada, Netherlands, Turkey, Chile, Germany, South Africa, Portugal
Sanofi Pasteur, a Sanofi Company

Completed

Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Poliomyelitis Vaccine

South Africa
Abcuro, Inc.
Syneos Health

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Inclusion Body Myositis

United States, Australia, Belgium, France, Canada, Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients (RESILIENT)

Sporadic Inclusion Body Myositis

United States, Belgium, Italy, Australia, Netherlands, Switzerland, France, United Kingdom, Denmark, Japan
Ipsen

Active, not recruiting

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. (PIVOINE)

Fibrodysplasia Ossificans Progressiva (FOP)

United States, France, Australia, Argentina, Italy, Canada, Sweden, United Kingdom, Brazil, Spain
Novartis Pharmaceuticals

Completed

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Sporadic Inclusion Body Myositis

United States, Belgium, Italy, Australia, Netherlands, Switzerland, France, United Kingdom, Denmark, Japan
Medical University of South Carolina
National Cancer Institute (NCI)

Completed

Herbal Mouthrinse for Oral Mucositis Study (OM)

Oral Mucositis

United States
Clementia Pharmaceuticals Inc.

Completed

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. (MOVE)

Fibrodysplasia Ossificans Progressiva

United States, Canada, France, Australia, Argentina, Brazil, Italy, Japan, Spain, Sweden, United Kingdom
Bristol-Myers Squibb

Completed

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Dermatomyositis | Polymyositis | Autoimmune Necrotizing Myopathy | Overlap Myositis | Juvenile Myositis Above the Age of 18

France, United States, Australia, Brazil, Czechia, Germany, Italy, Japan, Korea, Republic of, Mexico, Sweden
Amgen

Recruiting

A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Idiopathic Inflammatory Myositis

Mexico, United States, Spain, Australia, Italy, United Kingdom, Czechia, Brazil, Germany
Galera Therapeutics, Inc.

Completed

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

Radiation Induced Oral Mucositis

United States, Canada, Puerto Rico
CSL Behring

Terminated

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Oral Mucositis

United States, Canada, Australia, Germany, Italy, Austria
Chemo Mouthpiece

Completed

A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis

Oral Mucositis

United States
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA)

Myositis

United States, Korea, Republic of, Italy, United Kingdom, Hungary, Spain, Japan, Czechia, France, Mexico, Germany, Canada, Poland
Innovation Pharmaceuticals, Inc.

Completed

Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer (Brilacidin)

Head and Neck Neoplasms | Mucositis

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy

Acute Oral Mucositis Pain

United States
CuraGen Corporation

Completed

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

Stomatitis | Oral Mucositis

United States
Idera Pharmaceuticals, Inc.

Completed

Trial of IMO-8400 in Adult Patients With Dermatomyositis (8400-211)

Dermatomyositis

United States, Hungary, United Kingdom
Alexion Pharmaceuticals, Inc.

Active, not recruiting

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

Dermatomyositis

Italy, Spain, United States, France, Germany, Korea, Republic of, United Kingdom, Poland, Japan
Sucampo Pharma Americas, LLC

Terminated

Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy

Oral Mucositis

United States
Corbus Pharmaceuticals Inc.

Completed

Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis (DETERMINE)

Dermatomyositis

United States, Korea, Republic of, Japan, Spain, United Kingdom, Germany, Hungary, Bulgaria, Canada, Czechia, Italy, Poland, Sweden
Bilthoven Biologicals
Serum Institute of India Pvt. Ltd.

Completed

A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals

Immune Response to Oral Polio Vaccine

Bangladesh
Galera Therapeutics, Inc.

Completed

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

Oral Mucositis

United States, Puerto Rico, Canada
SciClone Pharmaceuticals

Unknown

Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer

Oral Mucositis

United States
Monopar Therapeutics

Terminated

Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. (VOICE)

Chemoradiotherapy-Induced Severe Oral Mucositis

United States, Spain, Germany, France, Puerto Rico
MedImmune LLC
PPD

Completed

A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis

Systemic Lupus Erythematosus

United States, Brazil, Canada, Chile
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Capsaicin Lozenges in Treating Patients With Mucositis Caused by Radiation Therapy

Head and Neck Cancer | Radiation Toxicity

United States
Soligenix

Completed

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

Oral Mucositis | Squamous Cell Carcinoma of the Oral Cavity and Oropharynx

United States, Spain, United Kingdom, France, Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis

Colombia, Costa Rica
Sanofi Pasteur, a Sanofi Company

Completed

A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis

Colombia, Costa Rica
Sanofi Pasteur, a Sanofi Company

Completed

Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Colombia, Costa Rica
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Pain | Head and Neck Cancer | Mucositis | Oral Complications of Radiation Therapy

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer

Head and Neck Cancer | Oral Complications

United States, Canada
MedImmune LLC

Completed

N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

United States, Czechia, Thailand, Germany, Korea, Republic of, Israel, New Zealand, Spain, Taiwan, Japan, Turkey, Hungary, Bulgaria, Mexico, Russian Federation, Colombia, Peru, Poland, Estonia, South Africa, Canada, Australia, Hong... and more
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat

Pain | Head and Neck Cancer | Cancer-related Problem/Condition

Canada, United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer

Head and Neck Cancer | Radiation Toxicity | Oral Complications

United States, Canada
Alexion

Active, not recruiting

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

United States, Australia, Austria, Canada, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Spain, United Kingdom
Alexion Pharmaceuticals

Terminated

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

Hong Kong, United States, United Kingdom, Croatia, Malaysia, Korea, Republic of, Turkey, Japan, Italy, Spain, Taiwan, Australia, Argentina, Thailand, Russian Federation, Czechia, Denmark, Germany
Alexion Pharmaceuticals

Completed

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

Hong Kong, Korea, Republic of, United States, Croatia, Australia, Canada, Malaysia, Japan, Italy, Turkey, Spain, Taiwan, Argentina, Colombia, Czechia, Denmark, Germany, Russian Federation, Thailand, United Kingdom
National Institute of Allergy and Infectious Diseases...
Rho Federal Systems Division, Inc.; Autoimmunity Centers of Excellence

Completed

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Systemic Lupus Erythematosus (SLE) | Multiple Sclerosis (MS) | Rheumatoid Arthritis (RA) | Juvenile Dermatomyositis (JDM) | Juvenile Idiopathic Arthritis (JIA) | Pemphigus Vulgaris | Systemic Sclerosis (SSc) | Pediatric SLE | Pediatric-Onset Multiple Sclerosis (POMS)

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

Sarcoma | Lymphoma | Kidney Cancer | Leukemia | Neuroblastoma | Oral Complications

United States, Israel, Australia, Canada
GlaxoSmithKline

Completed

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

United States
Sanofi

Completed

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Meningococcal Meningitis

United States

Clinical Trials on Myositis in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations